Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from FDA

'A landmark moment for the field': FDA approves first-ever gene therapy for inherited deafness

A gene therapy made by Regeneron is the first treatment of its kind approved for genetic hearing loss.

LiveScience

Marijuana Rescheduled

Plus: skyway socialism, reconsider the lobster, D.C.'s urban growth, and more...

Reason

‘Can I have some, please?’: has Trump opened the door to a psychedelic future?

Order to speed hallucinogen research hailed as ‘threshold moment’ but concerns remain over access and protections

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

RFK Jr.'s peptide push could become next wellness boom

The heavily touted but loosely regulated proteins could fuel the kind of boom we've seen with weight-loss drugs.

Axios

Remote Patient Monitoring vs Chronic Care Management vs RTM: What’s the Difference?

The healthcare industry is rapidly evolving, and digital health solutions are at the forefront of this transformation.

inkl

Gene therapy improves hearing in 90% of patients with inherited deafness in largest trial of its kind

A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called OTOF.

LiveScience

Trump's Embrace of Psychedelic Therapy Leaves Most Users on the Wrong Side of the Law

The medical model assumes that people should be allowed to use psychedelics only for government-approved reasons.

Reason

Read news from The Economist, FT, and more,
with one subscription

Cantaloupe recall upgraded in US over potentially deadly contamination concerns

Recalled fruit was distributed to retailers in four states

The Independent UK

The COVID Reckoning Doesn't Go Far Enough

Real medical freedom will require something greater than replacing the public health establishment: ending the FDA's monopoly.

Reason

Jazz Pharmaceuticals Stock, a Barchart Favorite, Trends Higher as Trump Renews Cannabis Hopes. Should You Buy JAZZ Here?

Jazz Pharmaceuticals stock pops as President Trump signals renewed urgency to reclassify cannabis as Schedule III drug. Technicals signal further upside ahead in JAZZ shares.

Barchart

The Promise and Limits of Trump's Psychedelic Therapy Order

The president's facilitation of research and FDA review could help make psychedelics available to approved patients. But what about everyone else?

Reason

This 4/20, Wall Street Is Betting on More Than Marijuana

Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.

MarketBeat

Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic medicines. But is it too late to invest in CMPS shares already?

Barchart

Trump Signs Psychedelics Order

Plus: ship seizures, the best free bread in America, and more...

Reason

Get all your
news in one place.

100's of premium titles.
One news app.

We Got This Covered

‘Do you want FDA approval?’: Trump wins over Joe Rogan by green-lighting a drug research idea he had from a podcast

Here is the most random way to get policy greenlit.

Axios

How Trump is wooing Joe Rogan after their split

The president knows that keeping Rogan close still matters.

International Business Times UK

Trump Signs Executive Order Endorsing Psychedelic Psilocybin and Ibogaine; Asks 'Can I Have Some, Please?'

President Trump signed an executive order to expedite the review and funding of psychedelic drugs such as psilocybin and ibogaine to treat serious mental illnesses and address public health crises.

Euronews

Trump signs order to fast-track research on psychedelic drugs

Trump signed an executive order Saturday to ease research restrictions on psychedelic drugs like psilocybin and LSD, aiming to accelerate studies into their potential for treating mental health conditions.

Get all your
news in one place.

100's of premium titles.
One news app.

Latin Times

Joe Rogan Puts Trump Feud Aside at White House, Pushes Psychedelic Drug Fast-Tracking for Mental Health

Joe Rogan took a break from publicly bashing President Donald Trump on Saturday and walked into the Oval Office for a cause he has championed for years: speeding access to psychedelic-based treatments for veterans struggling with addiction, post-traumatic stress disorder, and trauma.

The Times of India

What is Joe Rogan doing in the White House? Trump invites podcaster and calls him 'liberal'

Joe Rogan’s appearance at the White House alongside Donald Trump has raised eyebrows, after the MAGA podcast host joined the president during the signing of an executive order focused on psychedelic drug research for mental health treatment.

The Independent UK

Trump signs order to speed review of psychedelics, including the controversial drug ibogaine

President Donald Trump has directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine

We Got This Covered

New York woman arrested after her late son’s toxicology report revealed something unexpected

What's in your medicine cabinet?

International Business Times

Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum

Shares of Hims & Hers Health Inc. climbed sharply in morning trading Friday as investors bet that potential regulatory relief on compounded peptides could strengthen the telehealth company's weight-loss offerings and broader platform growth.

Newslaundry

Indian firms dumped Rs 1,000 crore of unapproved opioid pills into West Africa’s drug crisis

This article is the result of a collaboration with Netherlands-based open-source media outlet Bellingcat. Read Bellingcat’s editorially independent coverage here.

Barchart

RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?

Hims & Hers stock rallies as RFK Jr. says FDA may remove restrictions on certain peptides. But HIMS shares remain unattractive to own in 2026.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Harvard Medical School

128 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.